233 related articles for article (PubMed ID: 23652475)
21. [PCSK9 inhibitor is convincing a large analysis].
Schlimpert V
MMW Fortschr Med; 2015 Dec; 157(21-22):90. PubMed ID: 26960892
[No Abstract] [Full Text] [Related]
22. [Cholesterol associated to low density lipoproteins (LDL) and vascular risk reduction. Proprotein convertase subtilisin/kexin type 9 (PCSK9): A new therapeutic target].
Guijarro C; Ruilope LM
Med Clin (Barc); 2015 Jul; 145(2):67-9. PubMed ID: 26004275
[No Abstract] [Full Text] [Related]
23. [HDL, or non-HDL: that is the question. Possibilities of pharmacological treatment in residual dyslipidaemia].
Bajnok L
Orv Hetil; 2014 Jan; 155(2):62-8. PubMed ID: 24389322
[TBL] [Abstract][Full Text] [Related]
24. How far down to push the LDL cholesterol? PCSK9 where statins fail.
Simko V; Ginter E
Bratisl Lek Listy; 2016; 117(4):193-4. PubMed ID: 27075380
[No Abstract] [Full Text] [Related]
25. [Lipid control in high-risk patients: focus on PCSK9 inhibitors].
Filardi PP; Paolillo S; Trimarco B
G Ital Cardiol (Rome); 2015 Jan; 16(1):44-51. PubMed ID: 25689751
[TBL] [Abstract][Full Text] [Related]
26. Evolocumab (AMG 145) for primary hypercholesterolemia.
Langslet G; Emery M; Wasserman SM
Expert Rev Cardiovasc Ther; 2015 May; 13(5):477-88. PubMed ID: 25824308
[TBL] [Abstract][Full Text] [Related]
27. Reducing LDL with PCSK9 Inhibitors--The Clinical Benefit of Lipid Drugs.
Everett BM; Smith RJ; Hiatt WR
N Engl J Med; 2015 Oct; 373(17):1588-91. PubMed ID: 26444323
[No Abstract] [Full Text] [Related]
28. The ebbs and flows in the development of cholesterol-lowering drugs: prospects for the future.
Hajhosseiny R; Sabir I; Khavandi K; Wierzbicki AS
Clin Pharmacol Ther; 2014 Jul; 96(1):64-73. PubMed ID: 24699033
[TBL] [Abstract][Full Text] [Related]
29. Into the future: diversifying lipid management.
Tonkin AM; Watts GF
Lancet; 2012 Dec; 380(9858):1971-4. PubMed ID: 23141810
[No Abstract] [Full Text] [Related]
30. Familial hypercholesterolaemia: PCSK9 inhibitors are coming.
Santos RD; Watts GF
Lancet; 2015 Jan; 385(9965):307-10. PubMed ID: 25282517
[No Abstract] [Full Text] [Related]
31. CardioPulse: The European Medicines Agency's approval of proprotein convertase subtilisin/kexin type 9 inhibitors.
Blind E; de Graeff PA; Meurs I; Holtkamp F; Baczynska A; Janssen H
Eur Heart J; 2016 Feb; 37(6):502-3. PubMed ID: 26853264
[No Abstract] [Full Text] [Related]
32. New weapon in fighting atherosclerosis: effective inhibition of circulating low density lipoprotein cholesterol.
Ginter E; Simko V
Bratisl Lek Listy; 2014; 115(12):741-2. PubMed ID: 25520219
[TBL] [Abstract][Full Text] [Related]
33. Effect of a monoclonal antibody to PCSK9, REGN727/SAR236553, to reduce low-density lipoprotein cholesterol in patients with heterozygous familial hypercholesterolaemia on stable statin dose with or without ezetimibe therapy: a phase 2 randomised controlled trial.
Stein EA; Gipe D; Bergeron J; Gaudet D; Weiss R; Dufour R; Wu R; Pordy R
Lancet; 2012 Jul; 380(9836):29-36. PubMed ID: 22633824
[TBL] [Abstract][Full Text] [Related]
34. Antihyperlipidemic therapies targeting PCSK9: Novel therapeutic agents for lowering low-density lipoprotein cholesterol.
Liu MH
Int J Cardiol; 2015 Sep; 195():212-4. PubMed ID: 26048378
[No Abstract] [Full Text] [Related]
35. Effects of AMG 145 on low-density lipoprotein cholesterol levels: results from 2 randomized, double-blind, placebo-controlled, ascending-dose phase 1 studies in healthy volunteers and hypercholesterolemic subjects on statins.
Dias CS; Shaywitz AJ; Wasserman SM; Smith BP; Gao B; Stolman DS; Crispino CP; Smirnakis KV; Emery MG; Colbert A; Gibbs JP; Retter MW; Cooke BP; Uy ST; Matson M; Stein EA
J Am Coll Cardiol; 2012 Nov; 60(19):1888-98. PubMed ID: 23083772
[TBL] [Abstract][Full Text] [Related]
36. [Proprotein convertase subtilisin/kexin type 9 (PCSK9) and inhibitors].
Avci A; Demir K; Altunkeser BB
Turk Kardiyol Dern Ars; 2014 Oct; 42 Suppl 2():56-67. PubMed ID: 25693363
[TBL] [Abstract][Full Text] [Related]
37. [In addition to atorvastatin. Innovative antibody lowers LDL around 72%].
Einecke D
MMW Fortschr Med; 2012 Apr; 154(7):28. PubMed ID: 22558865
[No Abstract] [Full Text] [Related]
38. Proprotein convertase subtilisin/kexin 9 inhibitors: an emerging lipid-lowering therapy?
Dragan S; Serban MC; Banach M
J Cardiovasc Pharmacol Ther; 2015 Mar; 20(2):157-68. PubMed ID: 24938457
[TBL] [Abstract][Full Text] [Related]
39. PCSK9 inhibition with evolocumab (AMG 145) in heterozygous familial hypercholesterolaemia (RUTHERFORD-2): a randomised, double-blind, placebo-controlled trial.
Raal FJ; Stein EA; Dufour R; Turner T; Civeira F; Burgess L; Langslet G; Scott R; Olsson AG; Sullivan D; Hovingh GK; Cariou B; Gouni-Berthold I; Somaratne R; Bridges I; Scott R; Wasserman SM; Gaudet D;
Lancet; 2015 Jan; 385(9965):331-40. PubMed ID: 25282519
[TBL] [Abstract][Full Text] [Related]
40. Rescue therapy with PCSK9 inhibitors for patients with delayed diagnosis of heterozygous familial hypercholesterolemia: Redressing the balance of missed opportunities.
Vuorio A; Watts GF; Kovanen PT
J Clin Lipidol; 2016; 10(5):1278-9. PubMed ID: 27678448
[No Abstract] [Full Text] [Related]
[Previous] [Next] [New Search]
